B of A Securities analyst Tazeen Ahmad has maintained a Buy rating for Kymera Therapeutics and raised the price target from $110 to $125. This adjustment follows similar moves by Truist Securities and B. Riley Securities, reflecting updated valuation outlooks for the biopharmaceutical company.

Kymera Therapeutics trades on the NASDAQ under the ticker symbol KYMR. The endorsements from these firms signal confidence in the stock's trajectory despite shifting price objectives among analysts.

Kymera Therapeutics, Inc. has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, an oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis (AD). The completion occurred nearly six months ahead of anticipated timelines, allowing the company to accelerate its expected topline data readout. Kymera now anticipates reporting data by year-end 2026, compared to the previous guidance of mid-2027. Following the announcement, shares of Kymera Therapeutics Inc. (NASDAQ: KYMR) climbed significantly, trading higher by more than 21% on Thursday.

The BROADEN2 trial evaluates KT-621, a first-in-class oral small molecule degrader medicine designed for immunological diseases. "With enrollment now complete, we are positioned to bring forward our expected topline data readout to this year as well as accelerate our planned Phase 3 initiation, subsequent readouts, and NDA filing," said Nello Mainolfi, Founder, President, and CEO of Kymera Therapeutics.

Key Trial Milestones

Subject to regulatory discussions, Kymera expects to initiate Phase 3 trials for AD by mid-2027. Additionally, the company is conducting the BREADTH Phase 2b trial for asthma, with data expected in late 2027. The stock's current price of $121.03 is significantly above its moving averages, with the 20-day simple moving average (SMA) at $85.20, indicating a bullish trend. The Relative Strength Index (RSI) is currently at 84.74, suggesting that the stock is in overbought territory.